Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:01:01.600Z.
Calculation as of: 2026-10-06T15:01:01.600Z.
Quote observation: 2026-10-06T15:00:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
EARNINGS YIELD
N/A
Market Cap
$988.17M
Earnings Yield
6.65%
TTM Avg
5.51%
3Y Avg
5.51%
5Y Avg
5.51%
Market Cap
$992.21M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$996.75M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Earnings Yield
N/A
TTM Avg
2.18%
3Y Avg
3.28%
5Y Avg
2.72%
Market Cap
$1.03B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$943.53M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $992.49M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $988.17M | 6.65% | 5.51% | 5.51% | 5.51% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $992.21M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.75M | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 3.22% | 5.54% | 5.54% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | N/A | 2.18% | 3.28% | 2.72% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $943.53M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.05B | N/A | 17.88% | 17.88% | 17.88% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
